BXRX

Baudax Bio, Inc. [BXRX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BXRX Stock Summary

Top 10 Correlated ETFs

BXRX


Top 10 Correlated Stocks

BXRX


In the News

12:57 27 Sep 2023 BXRX

Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune

Baudax Bio (BXRX) soars on the acquisition of a private company, TeraImmune. The acquisition will help advance novel cell therapies for autoimmune diseases.

02:01 27 Sep 2023 BXRX

Why Is Baudax Bio (BXRX) Stock Up 130% Today?

Against a broadly positive backdrop due to cooling inflation data, Baudax Bio (NASDAQ: BXRX ) nevertheless managed to resoundingly steal the spotlight, skyrocketing into triple-digit percentage gains. The pharmaceutical company — which focuses on innovative products for acute care — announced the acquisition of Teralmmune, a privately held biotechnology firm focused on autoimmune disease therapies.

08:18 27 Sep 2023 BXRX

Baudax Bio shares jump on acquisition of TeraImmune

Shares of Baudax Bio BXRX, -1.85% jumped 25% premarket on Friday after the company announced the acquisition of TeraImmune, a privately held biotech developing Treg-based cell therapies for autoimmune diseases. TeraImmune has a cell therapy candidate to eliminate certain clotting factor inhibitors in patients with hemophilia A, a rare genetic bleeding disorder, Baudax said in a release.

10:22 27 Sep 2023 BXRX

Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data

New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.

09:00 27 Sep 2023 BXRX

Baudax Bio Announces Date of Reconvened Annual Meeting

MALVERN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care and related settings, recently announced that it has adjourned its Annual Meeting of Shareholders (the “Annual Meeting”) without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum.

04:05 27 Sep 2023 BXRX

Baudax Bio to Present at the Sidoti Virtual Investor Conference

MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference, taking place May 10-11, 2023.

08:41 27 Sep 2023 BXRX

Why Is Baudax Bio (BXRX) Stock Down 52% Today?

Baudax Bio (NASDAQ: BXRX ) stock is falling hard on Thursday after the pharmaceutical company announced a public stock offering. Baudax Bio reveals that it's selling 3,478,262 shares of BXRX stock in this offering.

03:22 27 Sep 2023 BXRX

Best Penny Stocks To Buy Now? 3 To Watch Today

Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?

04:01 27 Sep 2023 BXRX

Is the Pain Over for Baudax Bio Investors after a 70% Spike?

Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. While the interim positive outcome is based on a 20-patient group, it expects to complete the phase 2 trial with 80 patients by the end of the first quarter of 2023.

10:58 27 Sep 2023 BXRX

Why Is Baudax Bio (BXRX) Stock Up 50% Today?

What caused Baudax Bio (NASDAQ: BXRX ) stock to double earlier today? The catalyst was undoubtedly this morning's announcement concerning a Phase 2 clinical trial of Baudax Bio's novel product, BX1000.

BXRX Financial details

Company Rating
Neutral
Market Cap
3.17M
Income
-55.5M
Revenue
564K
Book val./share
-2.19
Cash/share
0.29
Dividend
-
Dividend %
-
Employees
9
Optionable
No
Shortable
Yes
Earnings
06 Nov 2023
P/E
-0.03
Forward P/E
-
PEG
0
P/S
5.05
P/B
-0.14
P/C
1.04
P/FCF
-0.18
Quick Ratio
0.07
Current Ratio
0.09
Debt / Equity
-0.82
LT Debt / Equity
-0.22
-
-
EPS (TTM)
-119.63
EPS next Y
-
EPS next Q
-0.1
EPS this Y
57051.13%
EPS next Y
-
EPS next 5Y
-95.57%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-314.29%
EPS Q/Q
-53.82%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.01%
Inst Trans
0%
ROA
-260%
ROE
359%
ROC
-4.39%
Gross Margin
-1054%
Oper. Margin
-669%
Profit Margin
-9841%
Payout
-
Shs Outstand
10.32M
Shs Float
6.58M
-
-
-
-
Target Price
-
52W Range
0.32-12.24
52W High
-
52W Low
-
RSI
21
Rel Volume
0.07
Avg Volume
2.14M
Volume
146.8K
Perf Week
-14.41%
Perf Month
-45.89%
Perf Quarter
-81.3%
Perf Half Y
-84.38%
-
-
-
-
Beta
2.05463
-
-
Volatility
0.02%, 0.05%
Prev Close
-2.35%
Price
0.303
Change
-13.43%

BXRX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0037.0319.733.82K
Net income per share
-11.36K-2.7K-5.82K-431.36-246.53K
Operating cash flow per share
-9.22K-7.49K-3.31K-900.11-83.71K
Free cash flow per share
-9.75K-7.72K-3.36K-903.81-83.77K
Cash per share
02.66K2.28K290.3115.84K
Book value per share
-10.54K-2.5K-1.11K241.62-73.02K
Tangible book value per share
-14.94K-6.78K-3.09K-193.27-79.42K
Share holders equity per share
-10.54K-2.5K-1.11K241.62-73.02K
Interest debt per share
0115.75836.43197.9284.91K
Market cap
63.54M64.7M18.83M16.78M1.06K
Enterprise value
63.54M47.73M-1.74M9.42M1.86M
P/E ratio
-0.86-3.59-0.24-0.710
Price to sales ratio
0038.1915.540
POCF ratio
-1.06-1.29-0.43-0.340
PFCF ratio
-1.01-1.26-0.42-0.340
P/B Ratio
-0.93-3.87-1.271.270
PTB ratio
-0.93-3.87-1.271.270
EV to sales
00-3.528.721.47
Enterprise value over EBITDA
-1.13-0.780.03-0.2-0.15
EV to operating cash flow
-1.06-0.950.04-0.19-0.07
EV to free cash flow
-1.01-0.930.04-0.19-0.07
Earnings yield
-1.16-0.28-4.12-1.41-77.52K
Free cash flow yield
-0.99-0.8-2.37-2.95-26.34K
Debt to equity
0-0.05-0.660.65-0.29
Debt to assets
00.010.140.160.71
Net debt to EBITDA
00.280.390.15-0.15
Current ratio
0.112.612.031.50.3
Interest coverage
00-55.03-8.25-2.7
Income quality
0.811.540.582.490.47
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000011.59
Research and developement to revenue
0018.432.893.06
Intangibles to total assets
0.810.530.380.450.21
Capex to operating cash flow
0.060.030.0100
Capex to revenue
00-1.3-0.19-0.02
Capex to depreciation
-8.72-3.09-0.25-0.07-0.01
Stock based compensation to revenue
0018.954.431.1
Graham number
51.91K12.32K12.07K1.53K636.41K
ROIC
1.071.1817.33-1.044.62
Return on tangible assets
-11.34-0.7-1.83-0.8-10.35
Graham Net
-15.94K-7.97K-3.88K-388.26-86.64K
Working capital
-20.27M12.42M18.59M7.85M-15.11M
Tangible asset value
-96.87M-45.25M-41.18M-10.58M-26.37M
Net current asset value
-100.86M-50.8M-46.82M-16.56M-27.93M
Invested capital
0-0.05-0.660.65-0.29
Average receivables
0025.5K296.5K438.5K
Average payables
4.9M1.46M1.96M2.56M2.7M
Average inventory
001.49M3.99M2.5M
Days sales outstanding
0037.76183.1896.36
Days payables outstanding
00769.83219.15204.5
Days of inventory on hand
00627.58746.720
Receivables turnover
009.671.993.79
Payables turnover
000.471.671.78
Inventory turnover
000.580.490
ROE
1.081.085.24-1.793.38
Capex per share
-532.39-222.22-47.99-3.71-60.24

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
1.670.80.41-0.010.01
Net income per share
-45.06-100.42-14.43-3.27-1.51
Operating cash flow per share
-40.21-13.14-5.04-2.01-0.71
Free cash flow per share
-40.32-13.21-4.99-2.01-0.71
Cash per share
29.0219.087.011.640.29
Book value per share
23.56-66.04-32.32-3.15-2.19
Tangible book value per share
-101.85-79.98-35.16-4.06-4.79
Share holders equity per share
23.56-66.04-32.32-3.15-2.19
Interest debt per share
63.28180.2810.72-3.821.8
Market cap
6.07M2.91M2.39M3.95M5.72M
Enterprise value
9.57M5.35M4.25M7.58M13.07M
P/E ratio
-0.19-0.02-0.06-0.13-0.19
Price to sales ratio
20.2312.237.69-282.03190.52
POCF ratio
-0.84-0.75-0.63-0.85-1.66
PFCF ratio
-0.84-0.75-0.64-0.85-1.66
P/B Ratio
1.43-0.15-0.1-0.54-0.54
PTB ratio
1.43-0.15-0.1-0.54-0.54
EV to sales
31.8922.4813.69-541.32435.69
Enterprise value over EBITDA
-2.630.31-0.63-1.62-12.81
EV to operating cash flow
-1.33-1.38-1.12-1.62-3.79
EV to free cash flow
-1.32-1.37-1.13-1.62-3.79
Earnings yield
-1.33-10.21-4.54-1.92-1.29
Free cash flow yield
-1.19-1.34-1.57-1.18-0.6
Debt to equity
2.06-0.41-0.29-1.02-0.82
Debt to assets
0.210.460.711.050.41
Net debt to EBITDA
-0.960.14-0.28-0.77-7.21
Current ratio
0.690.530.30.330.09
Interest coverage
-2.630.37-9.340.290
Income quality
0.960.130.410.630.47
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000075.13
Research and developement to revenue
3.042.713.35-208.3659.3
Intangibles to total assets
0.550.240.210.30.6
Capex to operating cash flow
00.01-0.0100
Capex to revenue
-0.07-0.080.1300
Capex to depreciation
-0.03-0.030.3800
Stock based compensation to revenue
1.121.320.74-13.646.6
Graham number
154.55386.26102.4415.228.62
ROIC
-0.58-1.470.59-40.16-10
Return on tangible assets
-0.44-2.22-1.37-1.54-0.86
Graham Net
-157.65-97.77-38.35-4.55-6.26
Working capital
-5.7M-10.01M-15.11M-8.26M-18.6M
Tangible asset value
-18.29M-23.67M-26.37M-9.44M-23.42M
Net current asset value
-24.13M-25.78M-27.93M-10.27M-30.14M
Invested capital
2.06-0.41-0.29-1.02-0.82
Average receivables
612K464.5K324K167.5K0
Average payables
3.17M3.34M3.77M3.88M4.83M
Average inventory
5.23M4.87M2.24M00
Days sales outstanding
184.8118.3697.2600
Days payables outstanding
763.88268.8873.75852.675.04K
Days of inventory on hand
1.31K333.55000
Receivables turnover
0.490.760.9300
Payables turnover
0.120.331.220.110.02
Inventory turnover
0.070.27000
ROE
-1.911.520.451.040.69
Capex per share
-0.11-0.070.0500

BXRX Frequently Asked Questions

What is Baudax Bio, Inc. stock symbol ?

Baudax Bio, Inc. is a US stock , located in Malvern of Pa and trading under the symbol BXRX

What is Baudax Bio, Inc. stock quote today ?

Baudax Bio, Inc. stock price is $0.303 today.

Is Baudax Bio, Inc. stock public?

Yes, Baudax Bio, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap